Attenuation of Cardiomyocyte Hypertrophy via Depletion Myh7 using CASAAV
Myh7 is a classic biomarker for cardiac remodeling and a potential target to attenuate cardiomyocyte (CM) hypertrophy. This study aimed to identify the dominant function of Myh7 after birth and determine whether its removal would affect CM maturation or contribute to reversal of pathological hypertr...
Gespeichert in:
Veröffentlicht in: | Cardiovascular toxicology 2021-03, Vol.21 (3), p.255-264 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Myh7
is a classic biomarker for cardiac remodeling and a potential target to attenuate cardiomyocyte (CM) hypertrophy. This study aimed to identify the dominant function of
Myh7
after birth and determine whether its removal would affect CM maturation or contribute to reversal of pathological hypertrophy phenotypes. The CASAAV (CRISPR/Cas9-AAV9-based somatic mutagenesis) technique was used to deplete
Myh6
and
Myh7
, and an AAV dosage of 5 × 10
9
vg/g was used to generate a mosaic CM depletion model to explore the function of
Myh7
in adulthood. CM hypertrophy was induced by transverse aortic constriction (TAC) in Rosa26
Cas9-P2A-GFP
mice at postnatal day 28 (PND28). Heart function was measured by echocardiography. Isolated CMs and in situ imaging were used to analyze the structure and morphology of CM. We discovered that CASAAV successfully silenced
Myh6
and
Myh7
in CMs, and early depletion of
Myh7
led to mild adulthood lethality. However, the
Myh7
PND28-knockout mice had normal heart phenotype and function, with normal cellular size and normal organization of sarcomeres and T-tubules. The TAC mice also received AAV-Myh7-Cre to produce
Myh7
-knockout CMs, which were also of normal size, and echocardiography demonstrated a reversal of cardiac hypertrophy. In conclusion,
Myh7
has a role during the maturation period but rarely functions in adulthood. Thus, the therapeutic time should exceed the period of maturation. These results confirm
Myh7
as a potential therapeutic target and indicate that its inhibition could help reverse CM hypertrophy. |
---|---|
ISSN: | 1530-7905 1559-0259 |
DOI: | 10.1007/s12012-020-09617-y |